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Abstract
Background: Knowledge of predominant microbial patterns in community-acquired pneumonia
(CAP) constitutes the basis for initial decisions about empirical antimicrobial treatment, so a
prospective study was performed during 2003–2004 among CAP of adult Chinese urban
populations.
Methods: Qualified patients were enrolled and screened for bacterial, atypical, and viral pathogens
by sputum and/or blood culturing, and by antibody seroconversion test. Antibiotic treatment and
patient outcome were also assessed.
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Results: Non-viral pathogens were found in 324/610 (53.1%) patients among whom M. pneumoniae
was the most prevalent (126/610, 20.7%). Atypical pathogens were identified in 62/195 (31.8%)
patients carrying bacterial pathogens. Respiratory viruses were identified in 35 (19%) of 184
randomly selected patients with adenovirus being the most common (16/184, 8.7%). The
nonsusceptibility of S. pneumoniae to penicillin and azithromycin was 22.2% (Resistance (R): 3.2%,
Intermediate (I): 19.0%) and 79.4% (R: 79.4%, I: 0%), respectively. Of patients (312) from whom
causative pathogens were identified and antibiotic treatments were recorded, clinical cure rate
with β-lactam antibiotics alone and with combination of a β-lactam plus a macrolide or with
fluoroquinolones was 63.7% (79/124) and 67%(126/188), respectively. For patients having mixed M.
pneumoniae and/or C. pneumoniae infections, a better cure rate was observed with regimens that
are active against atypical pathogens (e.g. a β-lactam plus a macrolide, or a fluoroquinolone) than
with β-lactam alone (75.8% vs. 42.9%, p = 0.045).
Conclusion: In Chinese adult CAP patients, M. pneumoniae was the most prevalent with mixed
infections containing atypical pathogens being frequently observed. With S. pneumoniae, the
prevalence of macrolide resistance was high and penicillin resistance low compared with data
reported in other regions.
Background
Community-acquired pneumonia (CAP) remains a com-
mon disease with high mobidity, mortality, and treatment
cost [1,2]. The microbial patterns reported for CAP differ
considerably, depending on epidemiologic area, patient
populations, and the extent and nature of the microbio-
logic techniques used. Knowledge of predominant micro-
bial patterns in CAP constitutes the basis for initial
decisions about empirical antimicrobial treatment [3].
However, no prospective study has been done to investi-
gate such patterns in a large Chinese population over sev-
eral districts at the same time.
In the present work, we conducted a prospective study of
the etiology of CAP in adult patients at 12 centers in 7
Chinese cities to assess the causative microbial spectrum,
the influence of patient age, previous antibiotic use, and
the Pneumonia Patient Outcomes Research Team (PORT)
category of pneumonia on microbial patterns in the dis-
ease [4]. Antimicrobial susceptibility of isolates from clin-
ical specimens was also tested to estimate the prevalence
of drug resistance of common CAP-causing bacteria, espe-
cially Streptococcus pneumoniae and Haemophilus influenzae.
Meanwhile the outcome of antibiotic therapy for CAP was
analyzed. The results revealed a different predominant
microbial spectrum and relatively higher penicillin sus-
ceptibility of S. pneumoniae in the Chinese population
than previously reported [5,6].
Methods
General information
A prospective study of the causes and antimicrobial treat-
ment outcome of CAP was conducted in consecutively
enrolled adult patients (age ≥ 18 years) between 1 Decem-
ber 2003 and 30 November 2004 at 12 centers in 7 Chi-
nese cities (Beijing, Shanghai, Shenyang, Xi'an, Chengdu,
Guangzhou, and Hangzhou). The cities were selected
according to their geographical locations: Beijing and
Shenyang lie in the north area, Guangzhou in the south
area, Shanghai and Hangzhou in the east area, and Xi'an
and Chengdu in the west area. The study year was divided
into four periods: December to February, March to May,
June to August, and September to November. Two central
laboratories, PLA General Hospital laboratory and Beijing
Union Medical College Hospital laboratory, conducted
pathogen identification and drug susceptibility testing.
Therapy was recommended according to the CAP guide-
lines from the Chinese Medical Association [7], but the
final drug choice was determined by attending physicians.
Informed consent was obtained from each patient before
sputum and blood sample collection. The protocol was
approved by the Ethics Committee for Clinical Studies at
PLA General Hospital (Protocol: 2003-#035).
Diagnostic criteria
According to the guidelines from the Chinese Medical
Association [7], CAP was defined as an acute infiltrate on
a chest radiograph and at least one of the following: (a)
new or escalating cough, sputum production, purulent
sputum, chest pain; (b) fever; (c) altered breath sounds
or/and rales; (d) white blood cell count: > 10 × 109/L or <
4 × 109/L. Patients were excluded if they had tuberculosis,
lung cancer, non-infective interstitial lung diseases, pul-
monary oedema, pulmonary lobe collapse, pulmonary
thromboembolism, pulmonary infiltration with eosi-
nophilia, or pulmonary angiitis. Atypical pathogens
defined as Mycoplasma pneumoniae, Chlamydophila pneumo-
niae, and Legionella spp. The microbial etiology of pneu-
monia was considered if one of the following criteria was
met: (1) valid sputum sample generating one or more pre-
dominant microbial pathogens; (2) blood culture produc-
ing a bacterial pathogen; (3) serologic conversion: e.g. a ≥BMC Infectious Diseases 2009, 9:31 http://www.biomedcentral.com/1471-2334/9/31
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4-fold increase in titers of antibodies to Mycoplasma pneu-
moniae, Chlamydophila pneumoniae, Legionella pneumophila,
or respiratory viruses (influenza virus A and B, adenovi-
rus, and respiratory syncytial virus).
Microbiological evaluation
Regular sputum sampling was done with most (590/610)
patients enrolled in the study, and blood samples were
taken if patients had a fever of > 38.5°C. Sputum was
Gram-stained. Representative sputum originated from the
lower respiratory tract was defined as that containing > 25
granulocytes and < 10 epithelial cells per low power field
microscopic view. Validated sputum and blood samples
were cultured; microorganisms were identified according
to standard methods [8].
Blood samples (6–8 ml) were collected aseptically from
patients. Acute sera were separated and stored at -80°C
until convalescent sera, obtained 2 to 4 weeks after the
acute specimen, were available for simultaneous testing
[9]. The antibody titer to M. pneumoniae was determined
by microparticle agglutination using the Serodia Myco®
commercial kit (Fujirebio, Japan). C. pneumoniae-specific
IgG antibody titers were determined by the indirect
immunofluorescence method using the FI2192-1010G
commercial kit (Euroimmun, Germany), as were antibod-
ies to 14 different serogroups of L. pneumophila. Respira-
tory virus antibodies (IgG) were detected by ELISA using
the Virion-Serion commercial kit (Febricant, Germany).
Antimicrobial susceptibility testing
MICs of isolates were determined at Beijing Union Medi-
cal College Hospital laboratory, using agar dilution
according to CLSI protocols. Breakpoint concentrations
used to interpret MIC data qualitatively were based upon
those published by the National Committee for Clinical
Laboratory Standards of the USA (NCCLS, 2004) [10].
The inocula comprised 104–105 cfu/spot, delivered with a
multipoint inoculator. Cultures were incubated with anti-
microbial agents selected on the basis of common empiric
therapy options in China.
Data collection
Clinical, radiographic, and laboratory data were recorded
on a data sheet and entered into a computer database. The
following data were recorded on enrolling: age, gender,
comorbidities, antimicrobial treatment prior to enrol-
ment, duration of symptoms before the diagnosis of
pneumonia, clinical symptoms (body temperature, pleu-
ritic chest pain, purulent sputum), vital signs (respiratory
rate, heart rate, arterial systolic and diastolic blood pres-
sure, presence of rales), haematology (total WBC with dif-
ferential counts, platelet count, hemoglobin), chest
radiographic pattern, and alcohol consumption.
Data on modifying or risk factors collected, included
underlying cardiopulmonary diseases, exposure to a child
in a day care center, residence in a nursing home, β-lactam
therapy within the past 3 months, broad-spectrum antibi-
otic therapy for > 7 d in the past two months, corticoster-
oid therapy (> 10 mg of prednisone per day), alcoholism,
previous pneumonia history, and malnutrition.
Antibiotic therapy analysis
According to the causative pathogens identified, we classi-
fied the patients into four groups for analysis of outcome
of antibiotic therapy. First group: M. pneumoniae and C.
pneumoniae mono- and co-infection; second group: bacte-
rial co-infection with M. pneumoniae, C. pneumoniae or
both; third group: L. pneumophila mono-infection or
mixed with other pathogens; and fourth group: bacterial
infection only. Clinical response, evaluated post-treat-
ment, was rated as cure (complete resolution of all signs
and symptoms of pneumonia), improvement, or lack of
progression for all abnormalities on chest radiograph
[11].
Statistical analysis
Statistical analysis was carried out using SAS (SAS Insti-
tute, Cary, NC, USA) version 8.2. Results are presented
descriptively (some expressed as mean ± SD). Data were
compared by use of the χ2 statistic or Fisher's exact test.
For all analyses, p < 0.05 was considered to be significant.
Results
General information
The 610 enrolled patients (382 male and 228 female) had
a mean age of 52.4 (± 20.0 SD) years. When stratified into
the five classes of the PORT cumulative point system [4],
most patients were in low-risk Classes I (33.8%), II
(36.2%) and III (15.9%); moderate-risk Class IV disease
was determined in 13.1% of patients, and high-risk Class
V in only 1.0%. Clinical symptoms, as well as modifying
and risk factors, are summarized in Table 1. Three hun-
dred forty two patients (56.1%) received antimicrobial
treatment prior to enrollment. Thirty eight percent of
patients had at least one co-morbid illness, with cardiac
co-morbidity being the most frequent condition (25.9%),
followed by pulmonary co-morbidity (12.8%).
Pathogens distribution
Of 610 patients, sputum samples were obtained in 590
patients, and blood samples for culture were available in
141 patients. Of the 590 patients with sputum samples, S.
pneumoniae was the most common bacterium identified,
accounting for 10.3%, followed by H. influenzae (9.2%).
Overall, non-viral pathogens were detected in 324 of the
610 patients (Table 2). Of these, 195 were detected by
sputum examination, 5 by hemoculture, and 191 by serol-BMC Infectious Diseases 2009, 9:31 http://www.biomedcentral.com/1471-2334/9/31
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ogy testing. The most common agent identified was M.
pneumoniae, which was found in 126 patients (20.7%). S.
pneumoniae  was identified in 63 patients (10.3%), fol-
lowed by H. influenzae in 56 patients (9.2%). The fre-
quency of other infective agents was 6.6% for C.
pneumoniae (40 patients), 6.1% for Klebsiella pneumoniae
(37 patients), 5.1% for L. pneumophila (31 patients), 3.8%
for Staphylococcus aureus (23 patients), 1.6% for Escherichia
coli  (10 patients), 1.3% for Moraxella catarrhalis (8
patients), and 1.0% for Pseudomonas aeruginosa (6
patients). Atypical pathogens accounted for 31.3% over-
all. In 184 patients whose sera antibody response to respi-
ratory viruses were analyzed, 35 patients (19.0%) were
tested positive for at least one viral infection. The distribu-
tion of viruses was listed in Table 3. Overall, adenovirus
was the most common, identified in 16 patients (8.7%),
followed by influenza virus B in 12 patients (6.5%), respi-
ratory syncytial virus in 8 patients (4.3%), and influenza
virus A in 5 patients (2.7%). In patients that tested posi-
tive for viral infections, mixed infections with an atypical
Table 1: Summary of characteristics of all enrolled patients with community-acquired pneumonia (n = 610)
n (%)*
Symptoms
Fever 455 (74.6)
Cough 582 (95.4)
Purulent sputum 536 (87.9)
Rales 402 (65.9)
Leukocytosis > 10 × 109/L 260 (42.6)
Modifying factors
Exposure to a child in a day care center 7 (1.2)
β-lactam therapy within the past 3 months 120 (19.7)
Broad-spectrum antibiotic therapy for > 7 d in the past two months 61 (10.0)
Corticosteroid therapy (> 10 mg of prednisone per day) 9 (1.5)
Alcoholism 1 (0.2)
History of pneumonia 79 (13.0)
Comorbidities
Cardiac 158 (25.9)
Pulmonary 78 (12.8)
Diabetes mellitus 33 (5.4)
Central nervous system 25 (4.1)
Renal 8 (1.3)
Hepatic 7 (1.1)
*Patient number, numbers in parenthesis are percentage of total patient number.
Table 2: Non-viral pathogens detected among 610 patients with community-acquired pneumonia
Pathogen Patients, n (%)
Mono-infection
Mycoplasma pneumoniae 82 (13.4)
Streptococcus pneumoniae 37 (6.07)
Haemophilus influenzae 33 (5.4)
Chlamydophila pneumoniae 29 (4.8)
Klebsiella pneumoniae 23 (3.8)
Staphylococcus aureus 17 (2.8)
Legionella pneumophila 17 (2.8)
Escherichia coli 6 (1.0)
Pseudomonas aeruginosa 5 (0.8)
Moraxella catarrhalis 5 (0.8)
Mixed infections 70 (11.5)
Two pathogens 64 (10.5)
Three pathogens 5 (0.8)
Four pathogens: 1 (0.2)
Total number of patients with identified pathogens 324 (53.1)
Note: Percentage of the most three common agents in which pathogens were identified was 38.9% for M. pneumoniae, 19.4% for S. pneumoniae, and 
17.3% for H. influenzae.BMC Infectious Diseases 2009, 9:31 http://www.biomedcentral.com/1471-2334/9/31
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pathogen or a bacterium were detected in 23 patients
(65.7%), accounting for 12.5% of the total 184 patients
tested for viral infection. The most common pathogen
involved in co-infection with virus was M. pneumonia,
accounting for 8 patients. The most common bacterium
found in co-infection was H. influenzae, accounting for 4
patients.
In addition to co-infection with respiratory viruses, mixed
infections were present in 70 of the 610 patients whose
microbial etiology was determined. Among these 70
patients, co-infection with two, three, and four pathogens
was detected in 64 (91.4%), 5 (7.1%), and 1 (1.4%)
patients, respectively. Among the 63 patients from whom
S. pneumoniae was identified, co-infection was detected in
26 (41.3%) patients (i.e.: M. pneumoniae in 15 (23.8%), C.
pneumoniae  in 3 (4.8%), and other pathogens in 8
(12.7%)). Where M. pneumoniae infection was detected, a
co-pathogen was diagnosed in 44 (34.9%) cases (S. pneu-
moniae in 15, H. influenzae in 13, and other pathogens in
16). Among the 195 patients with bacterial infection, an
atypical co-pathogen was identified in 62 (31.8%) cases.
M. pneumoniae were found less often in the elderly than in
patients aged ≤ 50 years (13.4% vs. 30.0%, p < 0.05). Co-
morbidity was found in 27.8% of M. pneumoniae-infected
patients. Age or co-morbidity alone had no impact on C.
pneumoniae infection, but C. pneumoniae was more fre-
quently found in elderly patients (> 70 years) without co-
morbid illness than in those with co-morbidity (18.4%
(7/38) vs. 6.3% (7/112), p < 0.05). Respiratory virus infec-
tion was less frequent in patients aged > 70 years than in
patients  ≤ 70 years old (0% vs. 24.6%, p  < 0.05). In
patients aged > 50 years, K. pneumoniae infection was
more frequent than in those aged ≤ 50 years (8.5% vs.
3.0%, p < 0.05). Five of the 6 patients with P. aeruginosa
infection were aged > 70 years. In patients with cardiovas-
cular or pulmonary co-morbidity, 12.4% (21/170) had K.
pneumoniae or P. aeruginosa infections, compared to only
5.0% (22/440) of patients without these co-morbidities (p
< 0.05).
56.1% of patients received antibiotics before enrolling. H.
influenzae  was 6-fold more frequently isolated from
patients who had not received antibiotics before enrolling
than those who had been treated with antibiotics (17.2%
(46/268) vs. 2.9% (10/342), p < 0.05). Prior antibiotic
therapy did not significantly reduce the frequency of S.
pneumoniae isolation.
Patients of PORT Classes I and II were more likely to have
S. pneumoniae and H. influenzae etiology. In patients with
Class V disease, association with K. pneumoniae was evi-
dent. M. pneumoniae was common in Class I, II, and III
disease, especially in Class I. With regard to seasonal vari-
ations, isolation rate of common pathogens did not show
any statistically significant differences in the four period
of our survey.
Antimicrobial susceptibility
A total of 63 isolates of S. pneumoniae were submitted for
antimicrobial susceptibility testing. The proportions of
intermediately or fully resistant isolates to penicillin were
19.0% and 3.2%, respectively. The prevalence of isolates
considered non-susceptible to azithromycin and new flu-
roquinolones were 79.4% and ≤ 6.3%, respectively (Table
4). In 56 isolates of H. influenzae tested, 8.4% produced
beta-lactamase and 11.9% were non-susceptible to ampi-
cillin.
Table 3: Respiratory viruses detected among 184 patients with 
community-acquired pneumonia
Pathogen Patients, n (%)
Mono-virus infection
influenza virus B 6 (3.3)
adenovirus 3 (1.6)
respiratory syncytial virus 2 (1.1)
influenza virus+ adenovirus 1 (0.5)
Mixed infections
Two pathogens 15 (8.2)
Three pathogens 6 (3.3)
Four pathogens 2(1.1)
Total 35 (19.0)
Note: Percentage of adenovirus in which viruses were identified was 
45.7%, and 34.3% for influenza virus B, 22.9% for respiratory syncytial 
virus, 14.3% for influenza virus A.
Table 4: Antimicrobial susceptibility of 63 S. pneumoniae isolates obtained in the study
Antimicrobial agent % of isolates MIC (μg/ml)
Susceptible Intermediate Resistant MIC50 MIC90 Range
Penicillin 77.8 19.0 3.2 0.016 0.5 0.016–4
Azithromycin 20.6 0.0 79.4 256 > 256 0.032–512
Amoxycillin/clavulanic acid 95.2 3.2 1.6 0.032 1 0.032–8
Levofloxacin 93.7 0.0 6.3 1 2 0.5–16
Gatifloxacin 93.7 0.0 6.3 0.25 0.5 0.125–4
Moxifloxacin 95.2 3.2 1.6 0.125 0.25 0.064–4BMC Infectious Diseases 2009, 9:31 http://www.biomedcentral.com/1471-2334/9/31
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Antibiotics usage and clinical outcome
In our study, the most frequently administered antibiotics
were  β-lactams, accounting for 73.6% (449/610), fol-
lowed by fluoroquinolones (49.8%, 304/610) and mac-
rolides (22.8%, 139/610). There was a total of 315
patients whose infecting pathogen was identified and
antibiotic usage was recorded. Since only 3 patients used
a macrolide as monotherapy, the clinical outcome of
these patients was not considered. In the other 312
patients, the clinical cure rate with β-lactam antibiotics
was 63.7% (79/124), with combination of a β-lactam plus
a macrolide or with fluoroquinolone (either alone or in
combination with other antibiotics) was 67% (126/188).
For patients affected by atypical pathogens, cure rates are
presented in Table 5. For mixed infections involving bac-
teria plus M. pneumoniae and/or C. pneumoniae, β-lactams
plus a macrolide or fluoroquinolone (alone or combined
with other antibiotics, e.g. regimens that are active against
atypical pathogens) showed a statistically significant
higher cure rate than β-lactams alone (75.8% v.s. 42.9%,
p = 0.045). In patients with co-morbid illness, the total
cure rate of therapy with the combination of a β-lactam
plus a macrolide or with fluoroquinolone was not signif-
icantly greater than that with β-lactams (40.4% vs. 50.0%,
p > 0.05).
Discussion
The distribution of pathogens associated with CAP is
attracting world-wide attention. The present study is the
first in China to prospectively investigate the pathogen
distribution in a large, broadly distributed patient popu-
lation. The study comprised several representative districts
and covered all seasons of the year. The data reveal a
unique pattern of pathogen distribution in CAP patients
in China and show a relatively higher susceptibility of S.
pneumoniae isolates to penicillin but relatively lower sus-
ceptibility to fluoroquinolones than that reported in
Europe and North America.
In previous studies, 30 to 60% of the CAP cases did not
yield an identifiable pathogen [12], in line with our
results. Although S. pneumoniae remains the most preva-
lent or frequently isolated etiologic agent in cases of CAP
[2,13], other organisms, such as H. influenzae and  M.
catarrhalis, as well as the so-called atypical pathogens,
including  M. pneumoniae,  C. pneumoniae, and L. pneu-
mophila, are now being reported more frequently than in
the past [14,15]. Atypical pathogens are responsible for 30
to 40% of cases of CAP [16]. In some reports, the infection
with atypical pathogens was more than with S. pneumo-
niae, especially for M. pneumoniae. Moola et al [15]
reported that when pathogens were confirmed in 131 of
504 patients, M. pneumoniae was found in 25% patients,
and S. pneumoniae in 22%. In a study performed in Spain
[16],  M. pneumoniae was the most frequent pathogen
(33%), with S. pneumoniae being found in only 19 of 110
patients with CAP.
In our study, the rate of atypical pathogen infection is
31.3% (if convalescent sera obtained longer than 4 weeks
after the acute specimen, L. pneumophila may be more, and
this percentage may be higher); M. pneumoniae is the most
prevalent etiologic agent, accounting for 20.7% of CAP
cases, i.e. more than those associated with S. pneumoniae.
Such finding is similar to our previous study between
2001 and 2002 in Beijing [9,17]. Previous reports show
that viral infection in patients with CAP varies from 4% to
39% [18], the most frequent being influenza spp. In the
present study, respiratory viruses account for 19.0% of
tested patients, with adenovirus being the most common.
Previous studies have shown that some patients with CAP
can have mixed infections involving both bacterial and
atypical pathogens [2,19]. C. pneumoniae is frequently
found in mixed infections and has been detected in over
half of cases with S. pneumoniae in reports from other
countries [2,19]. In our study, however, M. pneumoniae is
the most frequent co-infecting pathogen. Multiple simul-
Table 5: Cure rate [n (%)] of antibiotics in patients with CAP affected by atypical pathogens
Pathogens β-lactam alone β-lactam plus macrolides
or fluoroquinolone (alone
or combine with other
antibiotics)
MP, CP, MP+CP 25(62.5) 45(73.8)
MP+bacteria,
CP+bacteria,
MP+CP+bacteria
6(42.9) 25(75.8*)
LP or LP mixed with other pathogens 8(61.5) 10(55.6)
MP: Mycoplasma pneumoniae; CP: Chlamydophila pneumoniae; LP: Legionella pneumophila
*compared to β-lactam alone, p = 0.045BMC Infectious Diseases 2009, 9:31 http://www.biomedcentral.com/1471-2334/9/31
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taneous infections might interfere with the pulmonary
cleansing function and thus help establish setting for CAP
[20]. Pathogens such as C. pneumoniae induce ciliostasis in
human bronchial epithelial cells [21], and M. pneumoniae
exerts a toxic effect on ciliated human epithelium [22].
Currently, the clinical implications of mixed infections
are still undetermined. Influenza and other viruses can
cause primary viral pneumonia; secondary bacterial infec-
tions are common in hospitalized adults, and the reported
frequency has ranged widely, from 26% to 77% in differ-
ent studies [18]. The common cause of bacterial superin-
fection is S. pneumoniae. In our study, mixed infection of
respiratory viruses with other pathogens accounts for
12.5%. The most common co-infecting pathogen was M.
pneumoniae.
The impact of age is restricted to an association of younger
patients (age ≤ 50 years) with M. pneumoniae. This finding
is consistent with several previous studies [23,24], which
show that M. pneumoniae is the most common etiologic
agent in the 17–44 year age group. Patients without co-
morbid illnesses are also more likely to have M. pneumo-
niae infection. In our study, only 27.8% patients of M.
pneumoniae have co-morbid illnesses. It has been reported
that C. pneumoniae infection is more likely to occur in eld-
erly persons with co-morbid disease than in those who are
otherwise healthy [25]. However, our data showed a
higher incidence of C. pneumoniae infection in older
patients without co-morbid illness than with, contradict-
ing previous conclusion. An association of older age with
Gram-negative pathogens has been observed by several
groups [12,26]. It is well known that colonization of the
oropharyngeal mucosa by aerobic Gram-negative bacilli
increases with age [27]. In our study an age of > 50 years
was significantly associated with these pathogens. Pulmo-
nary co-morbidity also predisposes to pneumonia due to
K. pneumoniae or P. aeruginosa, probably due to previous
tracheabronchial colonization in COPD [28]. In our
study, Staphylococcus aureus was more frequent in PORT I
than in PORTs II through IV, probably due to patients
having low co-morbidities of diabetes mellitus and to
sample size being too small.
Antibiotic resistance in pneumococci is now considered to
be a global problem. The ANSORP (Asian network for sur-
veillance of resistant pathogens) study, conducted in
Asian countries from September 1996 to June 1997,
showed that the non-suscepibility to penicillin was as
high as 79.7% in Korea and non-susceptibility to erythro-
mycin was as high as 90.5% in Taiwan [29]. In China,
penicillin-non-susceptibile  S. pneumoniae ranged from
13.9% to 42.7%, and erythromycin-non-susceptibile S.
pneumoniae ranged from 42.5% to 83.6% in surveys con-
ducted from 1997 to 2003 [5,6,14,30-32]. Among the 63
strains of S. pneumoniae obtained from the present study,
non-susceptibility to penicillin was 22.2%; non-suscepti-
bility to azithromycin was 79.4%. In 2008 year, CLSI
changed the break point of penicillin for patients with
non-CNS infections, according to this, the non-suscepti-
bility to penicillin was only 3.2%. Although new fluoro-
quinolones have good activity against S. pneumoniae, the
resistance rate of new fluoroquinolones is higher in China
than that reported in other countries except for Hong
Kong [33], which is possibly a result of selective pressure
due to increased quinolone use in China.
American Thoracic Society guidelines [34] advocate that
all populations with CAP should be treated for possible
infection with atypical pathogens. Macrolides are recom-
mended as the first-line choice for outpatients. However,
such a recommendation may not be suitable for patients
in China because the prevalence of macrolide resistance is
so high (about 70% among S. pneumoniae isolates) and
because ermB-mediated high-level resistance is more fre-
quent than low-level resistance conferred by mefA (79.1%
contained the ermB gene, 10.8% contained the mefA gene,
and 10.1% harbored both the ermB and mefA genes) as
shown in our previous study [6]. In the present study, for
patients infected with M. pneumoniae and/or C. pneumo-
niae, the cure rate with β-lactams plus macrolides or with
fluoroquinolones was not significantly better than with β-
lactams alone. A meta-analysis also showed no advantage
of antibiotics active against atypical pathogens over β-
lactams [35]. Thus, β-lactams (penicillin, amoxicillin,
cephalosporins) should remain agents of choice in the
initial management of mild CAP without co-morbidity in
China. But for moderate or severe infection or in patients
with co-morbidities, therapy should be recommended
with either a β-lactam/macrolide combination or an anti-
pneumococcal fluoroquinolone alone [36-39].
Conclusion
In Chinese adult CAP patients, M. pneumoniae was the
most prevalent with mixed infections containing atypical
pathogens being frequently observed. With S. pneumoniae,
the prevalence of macrolide resistance was high and pen-
icillin resistance low compared with data reported in
other regions. β-lactams (penicillin, amoxicillin, cepha-
losporins) should remain agents of choice in the initial
management of mild CAP without co-morbidity in China.
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